Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.48%77 Operating Cash Flow per Share is $0.53 as of Mar. 2026. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 651 Medical Devices & Instruments companies, Coloplast AS ranks worse than 56.07% on this metric.
Coloplast AS's operating cash flow per share for the
three
months ended in Mar. 2026 was $0.10.
Coloplast AS's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.53.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Coloplast AS was 20.70% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 7.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -2.60% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 3.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Coloplast AS's Operating Cash Flow per Share or its related term are showing as below:
CLPBY'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -20.9 Med: 9.1 Max: 28.1
Current: 7.2
During the past 13 years, Coloplast AS's highest 3-Year average Operating Cash Flow per Share Growth Rate was 28.10% per year. The lowest was -20.90% per year. And the median was 9.10% per year.
CLPBY's 3-Year OCF Growth Rate is ranked worse than 56.07% of 651
companies
in the Medical Devices & Instruments industry
Industry Median: 12.5
vs CLPBY: 7.20
Coloplast AS Operating Cash Flow per Share Related Terms
Coloplast AS Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Operating Cash Flow per Share Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.53 mean?
Coloplast AS (CLPBY) has a Operating Cash Flow per Share of $0.53 as of Mar. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Coloplast AS and its competitors. According to the industry distribution chart, Coloplast AS ranks #365 out of 651 companies in the Medical Devices & Instruments industry, placing it in the top 56.1%.
Is Coloplast AS's Operating Cash Flow per Share too high?
Coloplast AS's current Operating Cash Flow per Share is $0.53. The Medical Devices & Instruments industry median Operating Cash Flow per Share is 12.50. Coloplast AS's value of $0.53 is 95.8% below this industry median. Based on the distribution chart, Coloplast AS ranks #365 out of 651 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Operating Cash Flow per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #365 out of 651 companies for Operating Cash Flow per Share. This places Coloplast AS in the lower half of its industry. The industry median Operating Cash Flow per Share is 12.50. Coloplast AS's value of $0.53 is 95.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.50, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Operating Cash Flow per Share of $0.53 is 95.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Operating Cash Flow per Share is $0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.70 — trading 48.7% below its estimated fair value. The current Operating Cash Flow per Share is $0.53 and 95.8% below the Medical Devices & Instruments industry median of 12.50. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Operating Cash Flow per Share is $0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.70 is trading 48.7% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Operating Cash Flow per Share: $0.53
GF Value™: $13.05 vs. price of $6.70 (48.7% below fair value)
Industry Position: 95.8% below the Medical Devices & Instruments median (#365 of 651)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
